Profil
Michael F.
Moloney served as Vice President-Information Systems & Technology at BioNumerik Pharmaceuticals, Inc. from 2000 to 2006.
He also served as Chief Operating Officer at OncoVista Innovative Therapies, Inc. from 2011 to 2014.
Moloney received his undergraduate degree from Alderson-Broaddus College and his MBA from The University of Texas at Austin.
Anciens postes connus de Michael F. Moloney
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOVISTA INNOVATIVE THERAPIES, INC. | Directeur des opérations | 11/02/2014 |
BioNumerik Pharmaceuticals, Inc.
 BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Directeur Technique/Scientifique/R&D | 01/12/2006 |
Formation de Michael F. Moloney
| Alderson-Broaddus College | Undergraduate Degree |
| The University of Texas at Austin | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ONCOVISTA INNOVATIVE THERAPIES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
BioNumerik Pharmaceuticals, Inc.
BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Health Technology |
